GenEdit has raised $8.5m in seed funding for its non-viral, nanoparticle delivery system for CRISPR. The funding was led by Bow Capital and Data Collective Bio, with participation from existing investors SK Holdings and Sequoia Capital. Last year, GenEdit’s CRISPR-Gold treatment was shown to successfully deliver treatment in mouse models of Duchenne muscular dystrophy. It has since broadened its reach. In June, researchers showed that CRISPR-Gold could deliver gene editing to the brain and amend the behaviour of mice with Fragile X syndrome, a common single-gene cause of autism spectrum disorder.
GenEdit has raised $8.5m in seed funding for its non-viral, nanoparticle delivery system for CRISPR. The funding was led by SK Holdings and Data Collective Bio, with participation from existing investors Bow Capital and Sequoia Capital. Last year, GenEdit’s CRISPR-Gold treatment was shown to successfully deliver treatment in mouse models of Duchenne muscular dystrophy. It has since broadened its reach. In June, researchers showed that CRISPR-Gold could deliver gene editing to the brain and amend the behaviour of mice with Fragile X syndrome, a common single-gene cause of autism spectrum disorder.